The invention relates to methods for treating or inhibiting SARS-CoV infection involving the administration of an interferon, particularly IFN .alpha.-n1, IFN .alpha.-n3, human leukocyte IFN .alpha. or IFN .beta.-1b.

 
Web www.patentalert.com

< Deglycosylated enzymes for conjugates

> Determination of vitamin D metabolite and displacement from plasma or serum binding proteins
~ 00493